vs
博士伦健康（BHC）与Compass, Inc.（COMP）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是Compass, Inc.的1.6倍（$2.8B vs $1.7B），Compass, Inc.净利率更高（-2.5% vs -3.7%，领先1.2%），Compass, Inc.同比增速更快（23.1% vs 9.3%），博士伦健康自由现金流更多（$403.0M vs $42.2M），过去两年Compass, Inc.的营收复合增速更高（27.0% vs 14.0%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
Compass, Inc.是美国主营住宅房产经纪业务的企业，其平台旗下有约3.3万名经纪人，大多为独立合同工，运营Compass、21世纪不动产、科威国际不动产、苏富比国际地产、佳士得国际地产等多个知名房产经纪品牌。
BHC vs COMP — 直观对比
营收规模更大
BHC
是对方的1.6倍
$1.7B
营收增速更快
COMP
高出13.9%
9.3%
净利率更高
COMP
高出1.2%
-3.7%
自由现金流更多
BHC
多$360.8M
$42.2M
两年增速更快
COMP
近两年复合增速
14.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $1.7B |
| 净利润 | $-103.0M | $-42.6M |
| 毛利率 | — | — |
| 营业利润率 | 17.0% | -2.5% |
| 净利率 | -3.7% | -2.5% |
| 营收同比 | 9.3% | 23.1% |
| 净利润同比 | -205.1% | -5.2% |
| 每股收益（稀释后） | $-0.30 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCCOMP
| Q4 25 | $2.8B | $1.7B | ||
| Q3 25 | $2.7B | $1.8B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.3B | $1.4B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.4B | $1.7B | ||
| Q1 24 | $2.2B | $1.1B |
净利润BHCCOMP
| Q4 25 | $-103.0M | $-42.6M | ||
| Q3 25 | $179.0M | $-4.6M | ||
| Q2 25 | $148.0M | $39.4M | ||
| Q1 25 | $-58.0M | $-50.7M | ||
| Q4 24 | $98.0M | $-40.5M | ||
| Q3 24 | $-85.0M | $-1.7M | ||
| Q2 24 | $10.0M | $20.7M | ||
| Q1 24 | $-64.0M | $-132.9M |
营业利润率BHCCOMP
| Q4 25 | 17.0% | -2.5% | ||
| Q3 25 | 23.1% | -0.4% | ||
| Q2 25 | 17.5% | 1.9% | ||
| Q1 25 | 12.2% | -4.0% | ||
| Q4 24 | 21.8% | -2.9% | ||
| Q3 24 | 12.7% | -0.2% | ||
| Q2 24 | 16.2% | 1.3% | ||
| Q1 24 | 13.1% | -12.5% |
净利率BHCCOMP
| Q4 25 | -3.7% | -2.5% | ||
| Q3 25 | 6.7% | -0.2% | ||
| Q2 25 | 5.8% | 1.9% | ||
| Q1 25 | -2.6% | -3.7% | ||
| Q4 24 | 3.8% | -2.9% | ||
| Q3 24 | -3.4% | -0.1% | ||
| Q2 24 | 0.4% | 1.2% | ||
| Q1 24 | -3.0% | -12.6% |
每股收益（稀释后）BHCCOMP
| Q4 25 | $-0.30 | $-0.07 | ||
| Q3 25 | $0.48 | $-0.01 | ||
| Q2 25 | $0.40 | $0.07 | ||
| Q1 25 | $-0.16 | $-0.09 | ||
| Q4 24 | $0.24 | $-0.08 | ||
| Q3 24 | $-0.23 | $0.00 | ||
| Q2 24 | $0.03 | $0.04 | ||
| Q1 24 | $-0.17 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $199.0M |
| 总债务越低越好 | $20.8B | — |
| 股东权益账面价值 | $-554.0M | $782.0M |
| 总资产 | $26.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHCCOMP
| Q4 25 | $1.3B | $199.0M | ||
| Q3 25 | $1.3B | $170.3M | ||
| Q2 25 | $1.7B | $177.3M | ||
| Q1 25 | $1.1B | $127.0M | ||
| Q4 24 | $1.2B | $223.8M | ||
| Q3 24 | $719.0M | $211.2M | ||
| Q2 24 | $595.0M | $185.8M | ||
| Q1 24 | $733.0M | $165.9M |
总债务BHCCOMP
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
股东权益BHCCOMP
| Q4 25 | $-554.0M | $782.0M | ||
| Q3 25 | $-565.0M | $773.3M | ||
| Q2 25 | $-764.0M | $719.9M | ||
| Q1 25 | $-1.2B | $635.0M | ||
| Q4 24 | $-1.3B | $409.4M | ||
| Q3 24 | $-1.2B | $428.0M | ||
| Q2 24 | $-1.2B | $398.4M | ||
| Q1 24 | $-1.1B | $330.3M |
总资产BHCCOMP
| Q4 25 | $26.4B | $1.5B | ||
| Q3 25 | $26.8B | $1.6B | ||
| Q2 25 | $27.3B | $1.6B | ||
| Q1 25 | $26.4B | $1.5B | ||
| Q4 24 | $26.5B | $1.2B | ||
| Q3 24 | $26.5B | $1.2B | ||
| Q2 24 | $26.5B | $1.2B | ||
| Q1 24 | $26.9B | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $45.3M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $42.2M |
| 自由现金流率自由现金流/营收 | 14.4% | 2.5% |
| 资本支出强度资本支出/营收 | 3.3% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $203.3M |
8季度趋势，按日历期对齐
经营现金流BHCCOMP
| Q4 25 | $495.0M | $45.3M | ||
| Q3 25 | $405.0M | $75.5M | ||
| Q2 25 | $289.0M | $72.8M | ||
| Q1 25 | $211.0M | $23.1M | ||
| Q4 24 | $601.0M | $30.5M | ||
| Q3 24 | $405.0M | $37.4M | ||
| Q2 24 | $380.0M | $45.0M | ||
| Q1 24 | $211.0M | $8.6M |
自由现金流BHCCOMP
| Q4 25 | $403.0M | $42.2M | ||
| Q3 25 | $314.0M | $73.6M | ||
| Q2 25 | $190.0M | $68.0M | ||
| Q1 25 | $96.0M | $19.5M | ||
| Q4 24 | $495.0M | $26.7M | ||
| Q3 24 | $334.0M | $32.8M | ||
| Q2 24 | $302.0M | $40.4M | ||
| Q1 24 | $129.0M | $5.9M |
自由现金流率BHCCOMP
| Q4 25 | 14.4% | 2.5% | ||
| Q3 25 | 11.7% | 4.0% | ||
| Q2 25 | 7.5% | 3.3% | ||
| Q1 25 | 4.2% | 1.4% | ||
| Q4 24 | 19.3% | 1.9% | ||
| Q3 24 | 13.3% | 2.2% | ||
| Q2 24 | 12.6% | 2.4% | ||
| Q1 24 | 6.0% | 0.6% |
资本支出强度BHCCOMP
| Q4 25 | 3.3% | 0.2% | ||
| Q3 25 | 3.4% | 0.1% | ||
| Q2 25 | 3.9% | 0.2% | ||
| Q1 25 | 5.1% | 0.3% | ||
| Q4 24 | 4.1% | 0.3% | ||
| Q3 24 | 2.8% | 0.3% | ||
| Q2 24 | 3.2% | 0.3% | ||
| Q1 24 | 3.8% | 0.3% |
现金转化率BHCCOMP
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | 1.85× | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | 2.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
COMP
暂无分部数据
